Health inequalities are differences in health status or the distribution of health determinants between distinct populations or groups. These have important impacts on the accessibility and effectiveness of cardiovascular disease preventive measures. This article discusses the most relevant issues on this topic.
AndersenRM. Revisiting the behavioral model and access to medical care: does it matter?J Health Soc Behav1995; 36(1): 1–10.
2.
BlackD. Inequalities in Health – Report of a Research Working Group, London, UK: Department of Health and Social Security, 1980.
3.
MarmotMAllenJBellR. WHO European review of social determinants of health and the health divide. Lancet2012; 380(9846): 1011–1029.
4.
PhelanJCLinkBGTehranifarP. Social conditions as fundamental causes of health inequalities: Theory, evidence, and policy implications. J Health Soc Behav2010; 51(Suppl.): S28–S40.
5.
TugwellPde SavignyDHawkerG. Applying clinical epidemiological methods to health equity: the equity effectiveness loop. BMJ2006; 332(7537): 358–361.
6.
HartJT. The inverse care law. Lancet1971; 1(7696): 405–412.
7.
PauwelsKHuysICasteelsM. Market access of cancer drugs in European countries: Improving resource allocation. Target Oncol2014; 9(2): 95–110.
8.
AlleyneGACasasJACastillo-SalgadoC. Equality, equity: Why bother?Bull World Health Organ2000; 78(1): 76–77.
9.
McLarenLMcIntyreLKirkpatrickS. Rose’s population strategy of prevention need not increase social inequalities in health. Int J Epidemiol2010; 39(2): 372–377.
CapewellSGrahamH. Will cardiovascular disease prevention widen health inequalities?PLoS Med2010; 7(8): e1000320–e1000320.
12.
MoscaLMcGillenCRubenfireM. Gender differences in barriers to lifestyle change for cardiovascular disease prevention. J Womens Health1998; 7(6): 711–715.
13.
HuntKWykeSGrayCM. A gender-sensitised weight loss and healthy living programme for overweight and obese men delivered by Scottish Premier League football clubs (FFIT): A pragmatic randomised controlled trial. Lancet2014; 383(9924): 1211–1221.
14.
ColellaTJGravelySMarzoliniS. Sex bias in referral of women to outpatient cardiac rehabilitation? A meta-analysis. Eur J Prev Cardiol2015; 22(4): 423–441.
15.
DollRPetoR. Mortality in relation to smoking: 20 years’ observations on male British doctors. Br Med J1976; 2(6051): 1525–1536.
16.
SagarVADaviesEJBriscoeS. Exercise-based rehabilitation for heart failure: Systematic review and meta-analysis. Open Heart2015; 2(1): e000163–e000163.
17.
MoscaLBarrett-ConnorEWengerNK. Sex/gender differences in cardiovascular disease prevention: What a difference a decade makes. Circulation2011; 124(19): 2145–2154.
18.
PiepoliMFHoesAWAgewallS. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J2016; 37(29): 2315–2381.
19.
PelletierRKhanNACoxJ. Sex versus gender-related characteristics: Which predicts outcome after acute coronary syndrome in the young?J Am Coll Cardiol2016; 67(2): 127–135.
20.
DoyleFMcGeeHConroyR. Systematic review and individual patient data meta-analysis of sex differences in depression and prognosis in persons with myocardial infarction: A MINDMAPS study. Psychosom Med2015; 77(4): 419–428.
21.
PruggerCWellmannJHeidrichJ. Regular exercise behaviour and intention and symptoms of anxiety and depression in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. Eur J Prev Cardiol2017; 24(1): 84–91.
22.
Stramba BadialeM. Women and research on cardiovascular diseases in Europe: A report from the European Heart Health Strategy (EuroHeart) project. Eur Heart J2010; 31: 1677–1685.
23.
BirdCESharmanZ. Gender-based analysis is essential to improving women’s health and health care. Womens Health Issues2014; 24(2): e163–e164.
24.
BucholzEMKrumholzHM. Women in clinical research: What we need for progress. Circ Cardiovasc Qual Outcomes2015; 8(2 Suppl. 1): S1–S3.
25.
DallongevillleJDe BacquerDHeidrichJ. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart2010; 96(21): 1744–1749.
26.
De SmedtDDe BacquerDDe SutterJ. The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. Int J Cardiol2016; 209: 284–290.
27.
HuxleyRBarziFWoodwardM. Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies. BMJ2006; 332(7533): 73–78.
28.
Kautzky-WillerAHarreiterJPaciniG. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev2016; 37(3): 278–316.
29.
VasanRSLarsonMGLeipEP. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med2001; 345(18): 1291–1297.
RosanoGMLewisBAgewallS. Gender differences in the effect of cardiovascular drugs: A position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J2015; 36(40): 2677–2680.
32.
LeweyJShrankWHBowryAD. Gender and racial disparities in adherence to statin therapy: A meta-analysis. Am Heart J2013; 165(5): 665–678.e1.
33.
SaxonDREckelRH. Statin intolerance: A literature review and management strategies. Prog Cardiovasc Dis2016; 59(2): 153–164.
34.
BarolettiSDell’OrfanoH. Medication adherence in cardiovascular disease. Circulation2010; 121(12): 1455–1458.
35.
BhuyanSSShiyanbolaOKediaS. Does cost-related medication nonadherence among cardiovascular disease patients vary by gender? Evidence from a nationally representative sample. Womens Health Issues2017; 27(1): 108–115.
36.
ZhangYLeachMJHallH. Differences between male and female consumers of complementary and alternative medicine in a national US population: A secondary analysis of 2012 NIHS data. Evid Based Complement Alternat Med2015; 2015: 413173–413173.
37.
JoshiRJanSWuY. Global inequalities in access to cardiovascular health care: Our greatest challenge. J Am Coll Cardiol2008; 52(23): 1817–1825.
38.
AnandSSHawkesCde SouzaRJ. Food consumption and its impact on cardiovascular disease: importance of solutions focused on the globalized food system: A report from the Workshop Convened by the World Heart Federation. J Am Coll Cardiol2015; 66(14): 1590–1614.
39.
LimSSVosTFlaxmanAD. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet2012; 380(9859): 2224–2260.
40.
MillerVYusufSChowCK. Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: Findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet Glob Health2016; 4(10): e695–e703.
41.
BumpJBReichMR. Political economy analysis for tobacco control in low- and middle-income countries. Health Policy Plan2013; 28(2): 123–133.
42.
KishoreSPBittonACraviotoA. Enabling access to new WHO essential medicines: The case for nicotine replacement therapies. Global Health2010; 6: 22–22.
43.
GraceSLTurk-AdawiKIContractorA. Cardiac rehabilitation delivery model for low-resource settings: An International Council of Cardiovascular Prevention and Rehabilitation consensus statement. Prog Cardiovasc Dis2016; 59(3): 303–322.
44.
YusufSIslamSChowCK. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): A prospective epidemiological survey. Lancet2011; 378(9798): 1231–1243.
45.
KhatibRMcKeeMShannonH. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: An analysis of the PURE study data. Lancet2016; 387(10013): 61–69.
46.
KurianAKCardarelliKM. Racial and ethnic differences in cardiovascular disease risk factors: A systematic review. Ethn Dis2007; 17(1): 143–152.
47.
CrookEDBryanNBHanksR. A review of interventions to reduce health disparities in cardiovascular disease in African Americans. Ethn Dis2009; 19(2): 204–208.
48.
KronishIMGoldfingerJZNegronR. Effect of peer education on stroke prevention: The prevent recurrence of all inner-city strokes through education randomized controlled trial. Stroke2014; 45(11): 3330–3336.
49.
GillJMCelis-MoralesCAGhouriN. Physical activity, ethnicity and cardio-metabolic health: Does one size fit all?Atherosclerosis2014; 232(2): 319–333.
50.
FolsomARArnettDKHutchinsonRG. Physical activity and incidence of coronary heart disease in middle-aged women and men. Med Sci Sports Exerc1997; 29(7): 901–909.
51.
GreggEWGerzoffRBCaspersenCJ. Relationship of walking to mortality among US adults with diabetes. Arch Intern Med2003; 163(12): 1440–1447.
52.
ForsythJSchoenthalerAChaplinWF. Perceived discrimination and medication adherence in black hypertensive patients: The role of stress and depression. Psychosom Med2014; 76(3): 229–236.
53.
PullenPRThompsonWRBenardotD. Benefits of yoga for African American heart failure patients. Med Sci Sports Exerc2010; 42(4): 651–657.
54.
SchneiderRHGrimCERainforthMV. Stress reduction in the secondary prevention of cardiovascular disease: Randomized, controlled trial of transcendental meditation and health education in blacks. Circ Cardiovasc Qual Outcomes2012; 5(6): 750–758.
55.
ParkIUTaylorAL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: A systematic review. Ann Fam Med2007; 5(5): 444–452.
56.
TaylorALWrightJTJr. Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: Lessons from the African–American Heart Failure Trial (A-HeFT), the African–American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation2005; 112(23): 3654–3660. discussion 3666.
57.
BangaloreSOgedegbeGGyamfiJ. Outcomes with angiotensin-converting enzyme inhibitors vs other antihypertensive agents in hypertensive blacks. Am J Med2015; 128(11): 1195–1203.
58.
YongCAzarbalFAbnousiF. Racial differences in quality of anticoagulation therapy for atrial fibrillation (from the TREAT-AF study). Am J Cardiol2016; 117(1): 61–68.
59.
RodriguezFCannonCPStegPG. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: Findings from the REACH registry. Clin Cardiol2013; 36(12): 721–727.
60.
ChoudhryNKFischerMASmithBF. Five features of value-based insurance design plans were associated with higher rates of medication adherence. Health Aff (Millwood)2014; 33(3): 493–501.
61.
CareyGCrammondBDe LeeuwE. Towards health equity: A framework for the application of proportionate universalism. Int J Equity Health2015; 14: 81–81.
62.
ViswanathanMGolinCEJonesCD. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: A systematic review. Ann Intern Med2012; 157(11): 785–795.
63.
KronishIMYeS. Adherence to cardiovascular medications: Lessons learned and future directions. Prog Cardiovasc Dis2013; 55(6): 590–600.
64.
GastonMHPorterGKThomasVG. Prime Time Sister Circles: Evaluating a gender-specific, culturally relevant health intervention to decrease major risk factors in mid-life African–American women. J Natl Med Assoc2007; 99(4): 428–438.
65.
Cardiovascular disease prevention for women attending breast and cervical cancer screening programs: The WISEWOMAN projects. The WISEWOMAN Workgroup. Prev Med1999; 28(5): 496–502.
66.
WoodDAKotsevaKConnollyS. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: A paired, cluster-randomised controlled trial. Lancet2008; 371(9629): 1999–2012.
67.
RoseG. The Strategy of Preventive Medicine, Oxford, UK: Oxford University Press, 1993.
68.
KivimakiMShipleyMJFerrieJE. Best-practice interventions to reduce socioeconomic inequalities of coronary heart disease mortality in UK: A prospective occupational cohort study. Lancet2008; 372(9650): 1648–1654.
69.
CareyGCrammondB. Systems change for the social determinants of health. BMC Public Health2015; 15: 662–662.
70.
Don de Savigny and Taghreed Adam (eds) Systems thinking for health systems strengthening. Alliance for Health Policy and Systems Research, WHO, 2009.
